Economic aspects of infertility care: a challenge for researchers and clinicians

P. G. Crosignani*, D. T. Baird, P. N. Barri, Siladitya Bhattacharya, P. Devroey, J. L. H. Evers, L. Gianaroli, E. Somigliana, J. S. Tapanainen, M. van Wely, K. Diedrich, L. Fraser, J. P. M. Geraedts, K. Lundin, A. Sunde, B. Tarlatzis, A. Van Steirteghem, A. Veiga, ESHRE Capri Workshop Group

*Corresponding author for this work

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Infertility care has improved remarkably over the last few decades and has received growing attention from health care providers. Several treatments, including expensive options such as Assisted Reproductive Techniques, are now widely available for routine clinical use. In most cases, adoption of these treatments has occurred without robust cost-effective analyses. IVF for unexplained infertility and ICSI in the absence of semen abnormalities are two examples of this gradual technology creep. More in-depth economic analyses in the field of infertility are undoubtedly warranted. However, performing these analyses is challenging because infertility care poses a number of unique challenges. Studies of cost-effectiveness are open to criticism because there is a lack of consensus about the outcomes of choice and the appropriate perspective. The use of quality adjusted life years (QALYs) to allow comparisons with other clinical conditions is also controversial because the value associated with infertility care cannot be easily captured in QALYs. Moreover, their use triggers the crucial question of whose QALYs merit consideration-an individual's, a couple's or a child's. In conclusion, economic analysis in infertility represents a peculiar but crucial challenge. If management of infertility is to become an integral part of publicly or privately funded health care systems worldwide, better quality data and a shared vision about the costs and benefits of infertility treatments are needed.

Original languageEnglish
Pages (from-to)2243-2248
Number of pages6
JournalHuman Reproduction
Volume30
Issue number10
Early online date3 Jul 2015
DOIs
Publication statusPublished - 1 Oct 2015

Keywords

  • infertility care
  • cost-benefit analysis
  • newborn's value
  • unexplained infertility
  • embryo transfer policy
  • in-vitro fertilization
  • intracytoplasmic sperm injection
  • single embryo-transfer
  • randomized controlled-trial
  • polycystic-ovary-syndrome
  • modified natural cycle
  • cost-effectiveness
  • assisted reproduction
  • elective single
  • tubal factor

Cite this

Crosignani, P. G., Baird, D. T., Barri, P. N., Bhattacharya, S., Devroey, P., Evers, J. L. H., ... ESHRE Capri Workshop Group (2015). Economic aspects of infertility care: a challenge for researchers and clinicians. Human Reproduction, 30(10), 2243-2248. https://doi.org/10.1093/humrep/dev163

Economic aspects of infertility care : a challenge for researchers and clinicians. / Crosignani, P. G.; Baird, D. T.; Barri, P. N.; Bhattacharya, Siladitya; Devroey, P.; Evers, J. L. H.; Gianaroli, L.; Somigliana, E.; Tapanainen, J. S.; van Wely, M.; Diedrich, K.; Fraser, L.; Geraedts, J. P. M.; Lundin, K.; Sunde, A.; Tarlatzis, B.; Van Steirteghem, A.; Veiga, A.; ESHRE Capri Workshop Group.

In: Human Reproduction, Vol. 30, No. 10, 01.10.2015, p. 2243-2248.

Research output: Contribution to journalArticle

Crosignani, PG, Baird, DT, Barri, PN, Bhattacharya, S, Devroey, P, Evers, JLH, Gianaroli, L, Somigliana, E, Tapanainen, JS, van Wely, M, Diedrich, K, Fraser, L, Geraedts, JPM, Lundin, K, Sunde, A, Tarlatzis, B, Van Steirteghem, A, Veiga, A & ESHRE Capri Workshop Group 2015, 'Economic aspects of infertility care: a challenge for researchers and clinicians', Human Reproduction, vol. 30, no. 10, pp. 2243-2248. https://doi.org/10.1093/humrep/dev163
Crosignani, P. G. ; Baird, D. T. ; Barri, P. N. ; Bhattacharya, Siladitya ; Devroey, P. ; Evers, J. L. H. ; Gianaroli, L. ; Somigliana, E. ; Tapanainen, J. S. ; van Wely, M. ; Diedrich, K. ; Fraser, L. ; Geraedts, J. P. M. ; Lundin, K. ; Sunde, A. ; Tarlatzis, B. ; Van Steirteghem, A. ; Veiga, A. ; ESHRE Capri Workshop Group. / Economic aspects of infertility care : a challenge for researchers and clinicians. In: Human Reproduction. 2015 ; Vol. 30, No. 10. pp. 2243-2248.
@article{4b67aacb7ce94fe385edf72b1383dc33,
title = "Economic aspects of infertility care: a challenge for researchers and clinicians",
abstract = "Infertility care has improved remarkably over the last few decades and has received growing attention from health care providers. Several treatments, including expensive options such as Assisted Reproductive Techniques, are now widely available for routine clinical use. In most cases, adoption of these treatments has occurred without robust cost-effective analyses. IVF for unexplained infertility and ICSI in the absence of semen abnormalities are two examples of this gradual technology creep. More in-depth economic analyses in the field of infertility are undoubtedly warranted. However, performing these analyses is challenging because infertility care poses a number of unique challenges. Studies of cost-effectiveness are open to criticism because there is a lack of consensus about the outcomes of choice and the appropriate perspective. The use of quality adjusted life years (QALYs) to allow comparisons with other clinical conditions is also controversial because the value associated with infertility care cannot be easily captured in QALYs. Moreover, their use triggers the crucial question of whose QALYs merit consideration-an individual's, a couple's or a child's. In conclusion, economic analysis in infertility represents a peculiar but crucial challenge. If management of infertility is to become an integral part of publicly or privately funded health care systems worldwide, better quality data and a shared vision about the costs and benefits of infertility treatments are needed.",
keywords = "infertility care, cost-benefit analysis, newborn's value, unexplained infertility, embryo transfer policy, in-vitro fertilization, intracytoplasmic sperm injection, single embryo-transfer, randomized controlled-trial, polycystic-ovary-syndrome, modified natural cycle, cost-effectiveness, assisted reproduction, elective single, tubal factor",
author = "Crosignani, {P. G.} and Baird, {D. T.} and Barri, {P. N.} and Siladitya Bhattacharya and P. Devroey and Evers, {J. L. H.} and L. Gianaroli and E. Somigliana and Tapanainen, {J. S.} and {van Wely}, M. and K. Diedrich and L. Fraser and Geraedts, {J. P. M.} and K. Lundin and A. Sunde and B. Tarlatzis and {Van Steirteghem}, A. and A. Veiga and {ESHRE Capri Workshop Group}",
note = "Funding: The meeting was organized by the European Society of Human Reproduction and Embryology with an unrestricted educational grant from Institut Biochimique S.A. (Switzerland).",
year = "2015",
month = "10",
day = "1",
doi = "10.1093/humrep/dev163",
language = "English",
volume = "30",
pages = "2243--2248",
journal = "Human Reproduction",
issn = "0268-1161",
publisher = "OXFORD UNIV PRESS",
number = "10",

}

TY - JOUR

T1 - Economic aspects of infertility care

T2 - a challenge for researchers and clinicians

AU - Crosignani, P. G.

AU - Baird, D. T.

AU - Barri, P. N.

AU - Bhattacharya, Siladitya

AU - Devroey, P.

AU - Evers, J. L. H.

AU - Gianaroli, L.

AU - Somigliana, E.

AU - Tapanainen, J. S.

AU - van Wely, M.

AU - Diedrich, K.

AU - Fraser, L.

AU - Geraedts, J. P. M.

AU - Lundin, K.

AU - Sunde, A.

AU - Tarlatzis, B.

AU - Van Steirteghem, A.

AU - Veiga, A.

AU - ESHRE Capri Workshop Group

N1 - Funding: The meeting was organized by the European Society of Human Reproduction and Embryology with an unrestricted educational grant from Institut Biochimique S.A. (Switzerland).

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Infertility care has improved remarkably over the last few decades and has received growing attention from health care providers. Several treatments, including expensive options such as Assisted Reproductive Techniques, are now widely available for routine clinical use. In most cases, adoption of these treatments has occurred without robust cost-effective analyses. IVF for unexplained infertility and ICSI in the absence of semen abnormalities are two examples of this gradual technology creep. More in-depth economic analyses in the field of infertility are undoubtedly warranted. However, performing these analyses is challenging because infertility care poses a number of unique challenges. Studies of cost-effectiveness are open to criticism because there is a lack of consensus about the outcomes of choice and the appropriate perspective. The use of quality adjusted life years (QALYs) to allow comparisons with other clinical conditions is also controversial because the value associated with infertility care cannot be easily captured in QALYs. Moreover, their use triggers the crucial question of whose QALYs merit consideration-an individual's, a couple's or a child's. In conclusion, economic analysis in infertility represents a peculiar but crucial challenge. If management of infertility is to become an integral part of publicly or privately funded health care systems worldwide, better quality data and a shared vision about the costs and benefits of infertility treatments are needed.

AB - Infertility care has improved remarkably over the last few decades and has received growing attention from health care providers. Several treatments, including expensive options such as Assisted Reproductive Techniques, are now widely available for routine clinical use. In most cases, adoption of these treatments has occurred without robust cost-effective analyses. IVF for unexplained infertility and ICSI in the absence of semen abnormalities are two examples of this gradual technology creep. More in-depth economic analyses in the field of infertility are undoubtedly warranted. However, performing these analyses is challenging because infertility care poses a number of unique challenges. Studies of cost-effectiveness are open to criticism because there is a lack of consensus about the outcomes of choice and the appropriate perspective. The use of quality adjusted life years (QALYs) to allow comparisons with other clinical conditions is also controversial because the value associated with infertility care cannot be easily captured in QALYs. Moreover, their use triggers the crucial question of whose QALYs merit consideration-an individual's, a couple's or a child's. In conclusion, economic analysis in infertility represents a peculiar but crucial challenge. If management of infertility is to become an integral part of publicly or privately funded health care systems worldwide, better quality data and a shared vision about the costs and benefits of infertility treatments are needed.

KW - infertility care

KW - cost-benefit analysis

KW - newborn's value

KW - unexplained infertility

KW - embryo transfer policy

KW - in-vitro fertilization

KW - intracytoplasmic sperm injection

KW - single embryo-transfer

KW - randomized controlled-trial

KW - polycystic-ovary-syndrome

KW - modified natural cycle

KW - cost-effectiveness

KW - assisted reproduction

KW - elective single

KW - tubal factor

U2 - 10.1093/humrep/dev163

DO - 10.1093/humrep/dev163

M3 - Article

VL - 30

SP - 2243

EP - 2248

JO - Human Reproduction

JF - Human Reproduction

SN - 0268-1161

IS - 10

ER -